Q3 2026 US Earnings Season: Broad Guidance Raises Signal Corporate Resilience

The Quick Take

• Over 20 US companies across sectors raised full-year guidance in Q3 2026 earnings calls.
• AbbVie beat Q3 revenue at $17.4B, lifted guidance on SKYRIZI and RINVOQ immunology strength.
• Altria raised guidance and its quarterly dividend despite ongoing cigarette volume pressure.
• Cheniere Energy posted record LNG export volumes and lifted 2026 EBITDA guidance.
• Xerox suspended its dividend, flagging restructuring challenges as the season's lone outlier.

Q3 2026 earnings season is delivering a broadly constructive read-through across US industries. Over twenty companies spanning healthcare, industrials, energy, defense real estate, and financial services raised full-year guidance in a single reporting cycle, reflecting resilient corporate demand and improving cost management. AbbVie's immunology franchise continued its post-Humira outperformance while Cheniere Energy posted record LNG export volumes against elevated global natural gas demand. Altria's guidance raise came despite secular cigarette volume pressure, suggesting the smoke-free portfolio transitions are gaining traction with investors and management alike.

The synchronized guidance raises signal that US corporate margins have absorbed the prior rate environment better than feared, challenging the bear case for late-cycle earnings deterioration. Phinia's record EPS and COPT Defense's raised FFO guidance reflect strength in auto components and defense contracting, sustaining rotational interest in industrials over expensive mega-cap technology names. TPG's $86 billion dry powder record is a positive forward indicator for private equity deployment across buyout and credit strategies. Xerox's dividend suspension stands as the outlier, highlighting structural pressure on legacy print hardware amid enterprise digitization.

Watch Q4 guidance language for inflation and labor cost signals, especially in healthcare, logistics, and energy utilities. Healthcare Realty's raised FFO guidance faces interest rate risk as cap rate pressure mounts on medical office assets. Mobileye's raised outlook sustains the autonomous driving supply chain thesis. The macro variable is the Federal Reserve's December FOMC stance: any hawkish pivot on the rate path would compress 2027 earnings multiples across most of these guidance-raisers and force management teams to revisit annual outlooks issued just weeks earlier.

Synthesized from 26 sources.